Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Abstract Background In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs). This post hoc analysis of SELECT-CHOICE, a phase 3 clinical trial, evaluated the impact of UPA vs abatacept (ABA) with backg...

Full description

Bibliographic Details
Main Authors: Martin Bergman, Namita Tundia, Naomi Martin, Jessica L. Suboticki, Jayeshkumar Patel, Debbie Goldschmidt, Yan Song, Grace C. Wright
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Patient-reported outcomes
Upadacitinib
JAK inhibitors
Targeted synthetic DMARDs
Online Access:https://doi.org/10.1186/s13075-022-02813-x

Internet

https://doi.org/10.1186/s13075-022-02813-x

Similar Items